Prevention of multiple system atrophy using human bone marrow-derived mesenchymal stem cells by reducing polyamine and cholesterol-induced neural damages

Stem Cell Res Ther. 2020 Mar 4;11(1):63. doi: 10.1186/s13287-020-01590-1.

Abstract

Background: Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder of unknown etiology, but is closely associated with damage to dopaminergic neurons. MSA progression is rapid. Hence, long-term drug treatments do not have any therapeutic benefits. We assessed the inhibitory effect of mesenchymal stem cells (MSCs) on double-toxin-induced dopaminergic neurodegenerative MSA.

Results: Behavioral disorder was significantly improved and neurodegeneration was prevented following MSC transplantation. Proteomics revealed lower expression of polyamine modulating factor-binding protein 1 (PMFBP1) and higher expression of 3-hydroxymethyl-3-methylglutaryl-CoA lyase (HMGCL), but these changes were reversed after MSC transplantation. In the in vitro study, the 6-OHDA-induced effects were reversed following co-culture with MSC. However, PMFBP1 knockdown inhibited the recovery effect due to the MSCs. Furthermore, HMGCL expression was decreased following co-culture with MSCs, but treatment with recombinant HMGCL protein inhibited the recovery effects due to MSCs.

Conclusions: These data indicate that MSCs protected against neuronal loss in MSA by reducing polyamine- and cholesterol-induced neural damage.

Keywords: Cholesterol; MSC; Multiple system atrophy (MSA); Polyamines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Cells / metabolism*
  • Cholesterol / adverse effects*
  • Humans
  • Male
  • Mesenchymal Stem Cells / metabolism*
  • Multiple System Atrophy / pathology
  • Multiple System Atrophy / prevention & control*
  • Multiple System Atrophy / therapy*
  • Polyamines / adverse effects*
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Wistar

Substances

  • Polyamines
  • Cholesterol